American Cancer Society now urges PSA tests every 2 years from age 50

• FYIEvidence Nov 12, 2026
  American Cancer Society now recommends PSA screening every 2 years from 50 to 69, ending its 2010 shared-decision stance
  Primary careUrology
  The American Cancer Society on Nov. 12 replaced its 2010 guideline, which called for most men to make a shared decision about testing, with a direct recommendation for PSA-based screening every two years for average-risk men 50 to 69 once they understand its benefits, limits and harms. Black men, and other men with a first-degree relative diagnosed before 65 or several affected first-degree relatives, are to be screened every year from 45 to 69; men with one first-degree relative diagnosed at 65 or older, every two years from 45. Screening is individualized at 70 to 74 and not recommended from 75, though very healthy men 75 to 79 with a rising PSA may continue. An elevated PSA is 3.0 ng/mL or higher at 45 to 69 and 6.5 ng/mL or higher at 70 to 74; the guideline calls for a repeat test two weeks to three months later, MRI or a validated biomarker to guide biopsy, and active surveillance as the first option for low-risk cancer. The society cited stronger evidence that screening lowers prostate cancer deaths and advanced-stage diagnoses; the guideline, led by Dr. Richard Hoffman and Dr. Robert Smith, appeared in CA: A Cancer Journal for Clinicians.
  Sources: American Cancer Society, CA: A Cancer Journal for Clinicians
• FYIWorkforce Nov 12, 2026
  Half of U.S. physicians now use AI every day, and three in four caught it in a factual error this year, Doximity survey finds
  All physicians
  In a September survey of 3,379 U.S. physician members, 52% said they use AI for work daily, up from 37% in 2025, and 85% at least weekly, up from 51%, Doximity said Nov. 12. About three in four reported at least one factual inaccuracy in the past 12 months, two-thirds said they verify AI-generated clinical information all or almost all of the time, and 28% said their organization has clear policies and approvals for AI use. More than 93% of oncologists use AI at least weekly, the highest of any specialty, and 46% of all respondents said AI has reduced their after-hours administrative work. About three in four said patients are more likely than six months ago to arrive with a self-diagnosis or treatment plan from a generative AI tool. Doximity sells its own AI tools to physicians and the figures are the company's; Healthcare Dive reported that use for clinical decision support rose to 63% from 37%.
  Sources: Doximity, Healthcare Dive
• FYIEvidence Nov 12, 2026
  A systolic target under 120 did not lower dementia or mild cognitive impairment in 12,434 adults with type 2 diabetes
  Primary careEndocrinology
  Treating systolic pressure to under 120 mm Hg instead of under 140 mm Hg did not reduce the combined rate of dementia or mild cognitive impairment over a median 3.8 years in adults with type 2 diabetes, according to a prespecified secondary analysis of the BPROAD trial published Nov. 12 in The BMJ. The open-label, assessor-masked randomized trial at 145 centers in China enrolled adults 50 and older with type 2 diabetes, raised systolic pressure and increased cardiovascular risk; 12,434 without probable dementia entered the cognitive analysis. Mean systolic pressure at one year was 121.6 mm Hg with intensive treatment and 133.2 mm Hg with standard treatment, and the composite outcome occurred at 3.69 and 3.89 events per 100 person-years (hazard ratio 0.96, 95% CI 0.86 to 1.06). In an MRI substudy of 862 participants, the intensive group accrued less white matter lesion volume, the authors reported.
  Sources: The BMJ, PubMed
• FYIRegulation Nov 13, 2026
  FDA clears AI that flags brain aneurysms larger than 3 mm on head CT angiography and tracks their growth between scans
  RadiologyNeurosurgery
  FDA cleared two 510(k)s, K262062 and K262147, for UPTUNITY Aneurysm, software that reads cerebral CT angiography, Bracco and Avicenna.AI said Nov. 13. The detection version is a concurrent reading aid for trained specialists that flags suspected saccular aneurysms larger than 3 mm and reports their location and size; the management version measures known aneurysms and compares exams over time to assess growth. The companies' release reports no sensitivity or specificity figures. "The clinical decision stays where it belongs: with the radiologist," said Cosimo DePinto of Bracco Americas. Avicenna.AI will lead U.S. sales, and the companies plan to show the product at RSNA in Chicago, which runs Nov. 29 to Dec. 3.
  Source: Bracco and Avicenna.AI
• FYIDeployment Nov 11, 2026
  MDCalc launches CrossCover, which strips patient identifiers from clinicians' questions to medical AI chatbots
  All physicians
  MDCalc, the clinical calculator and reference site, launched CrossCover on Nov. 11, a tool the company says is meant to help clinicians trust answers from medical AI chatbots while protecting patient and clinician privacy, STAT reported. CrossCover removes patient, provider and other identifying information from queries, and it does not require clinicians to register with national identification numbers or rely on agreements that allow them to enter protected health information, according to STAT. STAT contrasted the approach with OpenEvidence, Abridge and Epic, which are expanding the patient, provider and payer information their tools use. "We can take away some of the challenges and risks and problems with the technology," said Dr. Graham Walker, MDCalc's head of AI.
  Source: STAT